Previous close | 4.1800 |
Open | 4.1300 |
Bid | 4.4000 x 100 |
Ask | 4.4400 x 200 |
Day's range | 4.1300 - 4.4700 |
52-week range | 1.6600 - 8.0910 |
Volume | |
Avg. volume | 436,590 |
Market cap | 347.047M |
Beta (5Y monthly) | 2.62 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.6500 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 19.29 |
Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE™-1 Phase 1b Clinical Trial of TN-401 Announced Cost Containment Measures in Alignment with Focus on Generating Data from Clinical-Stage Gene Therapy Programs Raised $47 Million Net Proceeds in First Quarter Financing; Current Cash Runway into Second Half of 2025 SOUTH SAN FRANCISCO, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-
In this article, we will take a detailed look at the 13 Penny Stocks with Insider Buying in 2024. If you want to skip our detailed analysis and see the top 5 stocks in this list, click 5 Penny Stocks with Insider Buying in 2024. Insider transactions have always drawn market attention as it’s now a well-known fact […]
Abstracts Demonstrate Tenaya’s Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart MedicinesSOUTH SAN FRANCISCO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will present seven abstracts focused on the